-
Christen Countryteam
- logged in as: countryteam@sycamore.com
- Change Password
- Logout
- Manage Therapeutic Areas
- Manage Drugs/Treatments
- Manage Users
- 2
Project Description |
Alimta multi cohort trial |
Active Substance |
PHA2194694, anti-RCAI Ab |
Phase of Study |
Phase II/III |
Primary Objective |
The overall objectives are to evaluate the efficacy safety and tolerability of XDI POS in ESRD patients on hemodyalisis.
|
Clinical Development Plan |
Clinical Research Strategy for Anetumab Ravtansine |
Task | Status | Proposals / Comments | # Sites | # Countries | Updated |
---|---|---|---|---|---|
Early Indic. Feasibility |
Closed | No new activity | 70 | 35 | 14-Sep-2016 01:34pm |
Protocol Feasibility |
Closed | No new activity | 265 | 46 | 14-Sep-2016 01:34pm |
Site Feasibility |
Ongoing | 1 NEW FOR YOU | 270 | 55 | 14-Sep-2016 01:34pm |